Related Publications

XL184 / XL880

Bean J, Brennan C, Shih JY, et al. (2007). MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. PNAS 104(52):20932-7.
Birchmeier C, Birchmeier W, Gherardi E, et al. (2003). Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4(12):915-25.
Boccaccio C, Comoglio PM (2006). Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 6(8):637-45.
Bottaro DP, Liotta LA (2003). Cancer: Out of air is not out of action. Nature 423:593-5.
Christensen JG, Burrows J, Salgia R (2005). c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 225(1):1-26.
Corso, S, Comoglio, PM, Giordano S (2005). Cancer therapy: Can the challenge be MET? Trends Mol Med 11(6):284-92.
de Groot JW, Links TP, Plukker JT, et al. (2006). RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 27(5):535-60.
Eder JP, Appleman L, Heath E, et al. (2006). A phase I study of a novel spectrum selective kinase inhibitor (SSKI), XL880, administered orally in patients (pts) with advanced solid tumors (STs). J Clin Oncol 2006 ASCO Annual Meeting (Atlanta, GA, June 2-6) Proceedings Part I 24(18S):3041 (June 20 Suppl).
Eder JP, Heath E, Appleman L, et al. (2007). Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors. J Clin Oncol 2007 ASCO Annual Meeting (Chicago, IL, June 1-5) Proceedings 25(18S):3526 (June 20 Suppl).
Engelman, JA, Zejnullahu, K, Mitsudomi, T, et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039-43.
Joly AH (2006). Simultaneous blockade of VEGF and HGF receptors results in potent anti-angiogenic and anti-tumor effects. 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (Prague, Czech Republic, Nov 7-10) EJC Suppl 4(12):35. (Abstract 104).
Kurzrock R, Camacho L, Hong D, et al. (2006). A phase 1 dose-escalation study of the safety and pharmacokinetics of XL184, a VEGFR and Met kinase inhibitor, administered orally to subjects with advanced malignancies. 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (Prague, Czech Republic, Nov 7-10) EJC Suppl 4(12):124-5. (Abstract 405).
LoRusso P, Appleman L, Heath E, et al. (2005). A phase I study of a novel spectrum selective kinase inhibitor (SSKI), XL880, administered orally in patients with advanced solid tumors. 17th AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics (Philadelphia, PA, Nov 14-18) Clin Cancer Res 11(24) (Part 2):9025s. (Abstract A245).
LoRusso P, Appleman L, Zhu AX, et al. (2006). Pharmacodynamics of XL880, a novel spectrum selective kinase inhibitor (SSKI) administered orally in patients with advanced solid tumors (AST). 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (Prague, Czech Republic, Nov 7-10) EJC Suppl 4(12):124. (Abstract 404).
Ross RW, Srinivasan R, Vaishampayan U, et al. (2007). A phase 2 study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC). 19th AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics (San Francisco, CA, Oct 22-26). (Abstract B249).
Ross RW, Stein M, Sarantopoulos J, et al. (2007). A phase II study of the c-Met RTK inhibitor XL880 in patients (pts) with papillary renal-cell carcinoma (PRC). J Clin Oncol 2007 ASCO Annual Meeting Proceedings 25(18S):15601 (June 20 Supplement).
Salgia R, Hong DS, Camacho LH, et al. (2007). A phase I dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies. J Clin Oncol 2007 ASCO Annual Meeting (Chicago, IL, June 1-5) Proceedings 25(18S):14031 (June 20 Supplement).
Salgia R, Hong D, Sherman S, et al. (2007). A phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies. 19th AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics (San Francisco, CA, Oct 22-26). (Abstract A152).
Shapiro GI, Heath E, Malburg L, et al. (2007). A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics of XL880, a VEGFR and MET kinase inhibitor, administered daily to patients (pts) with advanced malignancies. 19th AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics (San Francisco, CA, Oct 22-26). (Abstract B248).
Zillhardt M, Sawada K, Jagadeeswaran, S, et al. (2008). The c-Met/VEGFR2 inhibitor XL880 inhibits ovarian cancer cell growth. Gynecologic Oncology 108:S132-3.

Back to XL184 Overview
Back to XL880 Overview

XL647

Cabebe E, Wakelee H (2007). Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol 8(1):15-27.
Ciardiello F, Tortora, G (2008). EGFR antagonists in cancer treatment. N Engl J Med 358(11):1160-74.
Ferrara N (2005). VEGF as a therapeutic target in cancer. Oncology 69 Suppl 3:11-16.
Ferrara N, Gerber HP, LeCouter J (2003). The biology of VEGF and its receptors. Nat Med 9(6):669-76.
Ferrara N, Hillan KJ, Gerber HP, et al. (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3(5):391-400.
Gendreau SB, Ventura R, Keast P, et al. (2007). Inhibition of the T790M Gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647(XL647), a novel spectrum-selective kinase inhibitor. Clin Canc Res 13(12):3713-23.
Heuer TS. (2007). ErbB2 mutations associated with in vitro lapatinib resistance and neoplastic transformation are sensitive to EXEL-7647 inhibition. AACR: Advances in Breast Cancer Research (San Diego, CA, Oct 17-20). (Abstract 6257).
Miller VA (2008). EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer. Sem Onc Nur 24(1):27-33.
Molina J, Wakelee, HA, Fehling, JM, et al. (2007). A phase I dose-escalation and pharmacokinetic (PK) study of XL647, a novel spectrum selective kinase inhibitor, administered orally daily to patients with advanced solid malignancies (ASM). 19th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (San Francisco, CA, Oct 22-26). (Abstract B242).
Mosesson Y, Yarden Y (2004). Oncogenic growth factor receptors: implications for signal transduction therapy. Semin Cancer Biol 14(4):262-70.
Normanno N, Bianco C, Strizzi L, et al. (2005). The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets 6(3):243-57.
Rizvi NA, Kris MG, Miller VA, et al. (2007). A phase II study of XL647 in non-small cell lung cancer (NSCLC) patients enriched for presence of EGFR mutations. 12th World Conference on Lung Cancer (Seoul, South Korea, Sept 2-6). J Thor Oncol 2(8) (Suppl 4): S737.
Rizvi, NA, Kris, M, Miller VA, et al. (2007). A phase II study of XL647 in non-small cell lung cancer (NSCLC) patients enriched for presence of EGFR mutations. 19th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (San Francisco, CA, Oct 22-26). (Abstract B124).
Sikic BI, Adjei, AA, Halsey J, et al. (2006). A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum-selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM). 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (Prague, Czech Republic, Nov 7-10). EJC Suppl 4(12):106-7. (Abstract 342).
Trowe T, Boukouvala S, Calkins K, et al. (2008). EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. Clin Cancer Res 14(8):2465-75.
Wakelee HA, Adjei AA, Halsey J, et al. (2006). A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM). J Clin Oncol 2006 ASCO Annual Meeting (Atlanta, GA, June 2-6) Proceedings Part I 24(18S):3044 (June 20 Suppl).
Wakelee HA, Adjei AA, Halsey J, et al. (2005). A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor (SSKI), XL647, in patients with advanced solid malignancies. 17th AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics (Philadelphia, PA, Nov 14-18) Clin Cancer Res 11(24) (Part 2):9029s. (Abstract A261).
Wakelee, HA, Adjei, AA, Keer H, et al. (2005). A phase I dose-escalation and pharmacokinetic (PK) study of a novel multiple-targeted receptor tyrosine kinase (RTK) inhibitor, XL647, in patients with advanced solid malignancies. J Clin Oncol 2005 ASCO Annual Meeting (Orlando, FL, May 13-17) Proceedings Part I 23(16S):3142 (June 1 Suppl).
Wakelee HA, Molina JR, Fehling JM, et al. (2007). A phase I study with exploratory pharmacodynamic endpoints of XL647, a novel spectrum selective kinase inhibitor, administered orally daily to patients (pts) with advanced solid malignancies. J Clin Oncol 2007 ASCO Annual Meeting (Chicago, IL, June 1-5) Proceedings 25(18S):14044 (June 20 Suppl).

Back to XL647 Overview

XL820

Aftab, D (2007). Targeting KIT with XL820 for the potential treatment of melanoma. 4th Int Melanoma Congr (New York, NY, November 1-4), Pigment Cell Res 20(6):509-12. (Abstract IS-56).
Carmeliet P (2005). VEGF as a key mediator of angiogenesis in cancer. Oncology 69 Suppl 3:4-10.
Curtin JA, Busam K, Pinkel D, et al. (2006). Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24(26):4340-6.
Fletcher JA, Rubin BP (2007). KIT mutations in GIST. Curr Opin Genet Dev 17(1):3-7.
Frohling S, Scholl C, Gilliland DG, et al. (2005). Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 23(26):6285-95.
Heinrich MC, Blanke CD, Druker BJ, et al. (2002). Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20(6):1692-1703.
Heuer TS (2007). XL820 inhibits mutated forms of KIT associated with drug resistance. 19th AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics (San Francisco, CA, Oct 22-26). (Abstract B237).
Laird AD, Cherrington JM (2003). Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin Investig Drugs 12(1):51-64.
Lennartsson J, Ronnstrand L (2006). The stem cell factor receptor/c-Kit as a drug target in cancer. Curr Cancer Drug Targets 6(1):65-75.
Papadopoulos KP, Rodon J, Mita A, et al. (2006). A phase 1 dose-escalation study of the safety and pharmacokinetics of a novel spectrum selective kinase inhibitor, XL820, administered orally to patients with solid tumors. 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (Prague, Czech Republic, Nov 7-10) EJC Suppl 4(12):33. (Abstract 97).
Rubin BP, Heinrich MC, Corless CL (2007). Gastrointestinal stromal tumour. Lancet 369(9574):1731-41.
Stein M, Yazji S, Rodon J, et al. (2007). A phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of XL820 administered orally daily (QD) or twice daily (BID) to patients (pts) with solid malignancies. 19th AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics (San Francisco, CA, Oct 22-26). (Abstract B69).

Back to XL820 Overview

XL147 / XL765

Arsham AM, Neufeld TP (2006). Thinking globally and acting locally with TOR. Curr Opin Cell Biol 18(6):589-97.
Berns K, Horlings HM, Hennessy BT, et al. (2007). A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12(4):395-402.
Cully M, You H, Levine AJ, et al. (2006). Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6(3):184-92.
DeCillis A, Baselga J, Edelman G, et al. (2008). PI3 kinase targeting agents: XL147 and XL765. 6th International Symposium on Targeted Anticancer Therapies (Bethesda, MD, Mar 20-22). Annals of Oncology 19(Suppl 3):16-23. (Plenary Lecture 30)
Denley A, Kang S, Karst U, et al. (2007). Oncogenic signaling of class I PI3K isoforms. Oncogene (Advance Online Publication, Nov 12):1-14.
Dillon RL, White DE, Muller WJ (2007). The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 26(9):1338-45.
Easton JB, Houghton PJ (2006). mTOR and cancer therapy. Oncogene 25(48):6436-46.
Foster P (2007). Potentiating the antitumor effects of chemotherapy with the selective PI3K inhibitor XL147. 19th AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics (San Francisco, CA, Oct 22-26). (Abstract C199).
Horn S, Bergholz U, Juecker M, et al. (2008). Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells. Oncogene (Advance Online Publication, March 3):1-11.
Laird D, et al. (2007). XL765 targets tumor growth, survival, and angiogenesis in preclinical models by dual inhibition of PI3K and mTor. 19th AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics (San Francisco, CA, Oct 22-26). (Abstract B250).
Paradiso A, Mangia A, Azzariti A, et al. (2007). Phosphatidylinositol 3-kinase in breast cancer: Where from here? Clin Cancer Res 13:5988-90.
Patnaik A, LoRusso P, Tabernero J, et al. (2007). Biomarker development for XL765, a potent and selective oral dual inhibitor of PI3K and mTOR currently being administered to patients in a phase I clinical trial. 19th AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics (San Francisco, CA, Oct 22-26). (Abstract B265).
Settleman J, Kurie JM (2007). Drugging the bad "AKT-TOR" to overcome TKI-resistant lung cancer. Cancer Cell 12(1):6-8.
Shapiro G, Edelman G, Calvo E, et al. (2007). Targeting aberrant PI3K pathway signaling with XL147, a potent, selective, and orally bioavailable PI3K inhibitor. 19th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (San Francisco, CA, Oct 22-26). (Abstract C205).
Vogt PK, Kang S, Elsliger M, et al. (2007). Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends in Biochemical Sciences 32(7):342-9.

Back to XL147 Overview
Back to XL765 Overview

XL019

Ahmed A, Chang C-C (2006). Chronic idiopathic myelofibrosis, clinicopathologic features, pathogenesis, and prognosis. Arch Pathol Lab Med 130:1133-43.
Barosi G, Bergamaschi G, Marchetti M, et al. (2007). JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 110(12):4030-6.
Barton BE, Karras, JG, Murphy TF, et al. (2004). Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther 3:11-20.
Flowers LO, Subramaniam PS, Johnson HM (2005). A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells. Oncogene 24(12):2114-20.
Haura EB, Turkson J, Jove R (2005). Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2(6):315-24.
Ihle JN, Gilliland DG (2007). Jak2: normal function and role in hematopoietic disorders. Curr Opin Genet Dev 17(1):8-14.
Levine RL, Gilliland DG (2007). JAK-2 mutations and their relevance to myeloproliferative disease. Curr Opin Hematol 14(1):43-7.
Renne C, Willenbrock K, Martin-Subero JI, et al. (2007). High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma. Leukemia 21(4):780-7.
Tefferi A, Gilliland DG (2005). JAK2 in myeloproliferative disorders is not just another kinase. Cell Cycle 4(8):1053-6.
Verstovsek S, Pardanani AD, Shah NP, et al. (2007). A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood (ASH Annual Meeting Abstracts) 110(11):553.
Wernig G, Mercher T, Okabe R, et al. (2006). Expression of Jak2 V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107(11):4274-81.
Yasuda Y, Fujita Y, Matsuo T, et al. (2003). Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 24(6):1021-9.

Back to XL019 Overview

XL281

Beeram M, Patnaik A, Rowinsky EK (2005). Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 23(27):6771-90.
Downward J (2003). Targeting RAS signaling pathways in cancer therapy. Nat Rev Cancer 3(1):11-22.
Malek S (2006). Selective Inhibition of RAF results in downregulation of the RAS/RAF/MEK/ERK pathway and inhibition of tumor growth in vivo. 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (Prague, Czech Republic, Nov 7-10) EJC Suppl 4(12):184. (Abstract 609).
Sebolt-Leopold JS, Herrera R (2004). Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4(1):937-47.

Back to XL281 Overview

XL518

Johnston, S (2007). XL518, a potent, selective orally bioavailable MEK1 inhibitor, down-regulates the Ras/Raf/MEK/ERK pathway in vivo, resulting in tumor growth inhibition and regression in preclinical models. 19th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (San Francisco, CA, Oct 22-26). (Abstract C209).
Kohno M, Pouyssegur J (2006). Targeting the ERK signaling pathway in cancer therapy. Ann Med 38(3):200-11.

Back to XL518 Overview

XL228

Aftab DT (2006). Simultaneous inhibition of IGF1R and SRC family kinases causes tumor growth inhibition and tumor regression in xenograft models. 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (Prague, Czech Republic, Nov 7-10) EJC Suppl 4(12):178. (Abstract 590).
Cortes J, Rousselot P, Kim DW, et al. (2007). Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109(8):3207-13.
Gontarewicz A, Balabanov S, Keller G, et al. (2008). Simultaneous targeting of Aurora kinases and BCR-ABL kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 111(8):4355-64.
Hochhaus A, Kantarjian HM, Baccarani M, et al. (2007). Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109(6):2303-9.
Mitsiades CS, Mitsiades NS, McMullan CJ, et al. (2004). Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5(3):221-30.
Parsons SJ, Parsons JT (2004). Src family kinases, key regulators of signal transduction. Oncogene 23(48):7906-9.
Pollak MN, Schernhammer ES, Hankinson SE (2004). Insulin-like growth factors and neoplasia. Nat Rev Cancer 4(7):505-18.
Shah, NP, Kasap C, Paquette R, et al. (2007). Targeting drug-resistant CML and Ph+-ALL with the spectrum selective protein kinase inhibitor XL228. Blood (ASH Annual Meeting Abstracts) 110(11):474. (Abstract 474).
Shah NP, Sawyers CL (2003). Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 22(47):7389-95.
Shah NP, Tran C, Lee FY, et al. (2004). Overriding imatinib resistance with a novel Abl kinase inhibitor. Science 305:399-401.
Weisberg E, Manley PW, Cowan-Jacob SW, et al. (2007). Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7(5):345-56.
Yeatman TJ (2004). A renaissance for SRC. Nat Rev Cancer 4(6):470-80.
Yee D (2006). Targeting insulin-like growth factor pathways. Br J Cancer 94(4):465-8.
Zhang W (2006). Inhibition of the drug-resistant T315I mutant of BCR-ABL. 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (Prague, Czech Republic, Nov 7-10) EJC Suppl 4(12):54. (Abstract 171).

Back to XL228 Overview

XL844

Bartek J, Lukas J (2003). Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3(5):421-9.
Clary DO (2007). Inhibition of Chk kinases in a leukemia model abrogates DNA damage checkpoints and promotes mitotic catastrophe. Proc Am Assoc Cancer Res 48. (Abstract 5385).
Janetka JW, et al. (2007). Inhibitors of checkpoint kinases: from discovery to the clinic. Curr Opin Drug Discov Devel 10(4):473-86.
Matthews DJ (2007). In vitro and in vivo potentiation of cytotoxic therapy by XL844, an orally bioavailable inhibitor of Chk1 and Chk2. 19th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (San Francisco, CA, Oct 22-26). (Abstract B228).
Matthews DJ (2006). Dissecting the roles of Chk1 and Chk2 in mitotic catastrophe using chemical genetics. 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (Prague, Czech Republic, Nov 7-10) EJC Suppl 4(12):107. (Abstract 344).
Matthews DJ, Yakes FM, Chen J, et al. (2007). Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 6(1):104-10.
Zhou BB, Bartek J (2004). Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 4(3):216-25.

Back to XL844 Overview